Several major U.S. health-care companies have lifted their 2025 profit targets after reporting stronger-than-expected second-quarter results, signalling resilient demand for innovative drugs and medical devices despite ongoing pricing pressures. Biogen raised its full-year adjusted earnings forecast to $15.50–$16.00 a share from $14.50–$15.50, crediting accelerating sales of Alzheimer’s therapy Leqembi and rare-disease drug Skyclarys. The stock gained nearly 8% in pre-market trading. AbbVie also upgraded guidance as immunology medicines Skyrizi and Rinvoq continued to offset declining Humira revenue. The company posted non-GAAP earnings of $2.97 a share on revenue of $15.42 billion, both ahead of analyst estimates. Medical-device maker Boston Scientific lifted its full-year adjusted EPS range to $2.95–$2.99 after quarterly sales climbed to $5.06 billion and adjusted profit reached $0.75 a share, beating consensus. Growth was driven by cardiovascular products such as Farapulse and Watchman. Johnson & Johnson, which reported earlier in July, also increased its outlook following better-than-forecast quarterly results. Bristol Myers Squibb trimmed its earnings target to $6.35–$6.65 a share but raised revenue guidance to up to $47.5 billion after quarterly sales of $12.27 billion topped projections. Baxter International missed consensus on both revenue and profit, and its shares fell about 11% in early trading.